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Summary We have investigated the capability of differentiation of Ewing's sarcoma (ES) towards a neuronal
direction through the establishment of four extraosseous ES cell lines and by in vitro stimulation with
dibutyryladenosine cyclic monophosphate (db-cAMP) of eight ES lines. All except one of the lines expressed
the molecule defined by 5CII, the antibody specifically reactive with ES. Two ES lines expressed a 200
kilodalton (kD) neurofilament protein (NFP) although their original tumours were negative for NFP.
Elongation ofcytoplasmic processes and increased NFP expression were observed after db-cAMP treatment of
these lines and microtubules in the cytoplasmic processes were ultrastructurally demonstrated. Six lines were
NFP negative, but three lines changed their morphology after induction of 200 kD NFP expression by
db-cAMP treatment. The other three showed no definitive differentiation after db-cAMP treatment. Chromo-
somal analysis of the new ES lines showed the typical t(11;22) in one line and a +der(22) in two lines. No
correlation was observed between the chromosomal abnormality and the differentiation capability. We
conclude that ES is a heterogeneous group of tumours with respect to capability of differentiation into the
neuronal lineage, but it is clearly distinguished from peripheral primitive neuroectodermal tumours by its 5C1 1
reactivity.
In 1921 Ewing (1921) first described a tumour originating
from bone in childhood. Later Tafft et al. (1969) and Anger-
vall and Enzinger (1975) reported sarcomas originating from
extraosseous tissue with characteristics similar to those of
Ewing's sarcoma (ES). Periodic reports of osseous and extra-
osseous ES have appeared, but their histogenesis is little
understood. Recently, it has become evident that some ES
cell lines have the capability of differentiation towards a
neuronal direction (Cavazzana et al., 1987) and some ESs
have been shown to possess a specific chromosomal trans-
location t(11;22) (Aurius et al., 1983; Turc-Carel et al., 1983)
and proto-oncogene expression. Some of these features are
shared with peripheral primitive neuroectodermal tumours
(Whang-Peng et al., 1984; McKeon et al., 1988), a tumour
closely related to ES. Dehner (1986) divided this particular
primitive tumour involving central and peripheral nervous
tissue into two groups, central and peripheral primitive
neurorectodermal tumours. The latter group has been report-
ed variously in the literature as peripheral neuroepitherioma
(Whang-Peng et al., 1984; Voss et al., 1984), peripheral
neuroblastoma and peripheral neuroectodermal tumour
(Schmidt et al., 1985; Juergens et al., 1988). We use the term
peripheral primitive neuroectodermal tumour (PNET) for
such a tumour in this report. Differential diagnosis between
ES and PNET is still controversial and some diagnostic
criteria have been proposed (Navas-Paracios et al., 1984). We
recently produced a monoclonal antibody, 5Cl 1, which clear-
ly divides these categories into two groups, 5Cll positive ES
and 5Cl negative PNET (Hara et al., 1989). The purpose of
this study is to characterise the capability of ES to differ-
entiate towards a neuronal direction through the establish-
ment of in vitro cell lines, in order to study the histogenesis
of ES. We show that ES comprises a heterogeneous group
with regard to its differentiation potential including tumours
showing no capacity for differentiation and those with vari-
able differentiation. We also propose new histopathological




Case 1 (Original tumour of NCR-EWI): The patient was a
10 year old boy who had a tumour mass in his neck. The
tumour was resected and one part was transplanted subcu-
taneously into the backs of nude mice. Serial transplantation
was carried out as described previously (Hata et al., 1980).
Case 2 (Original tumour ofNCR-EW2): The patient was a
13 year old boy who had a tumour in the pelvis. Computed
tomography revealed a soft tissue tumour involving the sac-
ral bone and the inferior vena cava. No distant metastasis
was found. Urinary and serum catecholamine and its meta-
bolite levels were within normal range. A biopsy specimen
was used in this study.
Case 3 (Original tumour ofNCR-EW3): The patient was a
10 year old boy who had a tumour mass in the chest wall.
Urinary and serum catecholamine and its metabolite levels
were not elevated. After chemotherapy and radiation treat-
ment, the tumour was resected.
Case 4 (Original tumour ofNCR-EW4): The patient was a
14 year old girl who was hospitalised for severe dyspnea.
Laboratory examination revealed that she had a tumour
mass in the chest wall accompanied by hemothorax. Pleural
effusion was aspirated to obtain a tumour sample. She soon
died of respiratory distress, but autopsy was not permitted.
Tissue preparation
The surgically resected tumours were immediately frozen in
OCT-compound (Tissue Tek Division, Miles Scientific Lab-
oratories Inc, Napervill, III, USA) and stored at - 80°C until
use. Tumour were also fixed in 20% buffered formalin and
embedded in paraffin for routine histological examination or
fixed in 2.5% glutaraldehyde, dehydrated in graded alcohol
and embedded in Epon 812 for electron microscopic observa-
tion. Cells in suspension were deposited on glass slides by
centrifugation in a Cytospin (Shandon Southern Products
Ltd, Cheshire, England) and were used for immunohisto-
chemical study.
Immunohistochemistry
Indirect immunoperoxidase staining was performed on ace-
tone-fixed frozen sections by using monoclonal antibodies
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(MoAbs). MoAb 5Cl1 was produced in our laboratory and
its specificity was described previously (Hara et al., 1989).
Briefly, 5Cll defines a cell surface protein with a molecular
weight of 81,000 daltons preferentially expressed on ES but
not on neuroblastoma and PNET cells. Two MoAbs, against
neurofilament protein (NFP), anti-68 kilodalton (kD) NFP
(Dakopatts, Glostrup, Denmark) and anti-200 kD NFP
(Labsystem, Helsinki, Finland), were also used. In addition,
anti-desmin (Dakopatts, Glostrup) was used in this study.
Cell lines
Four new ES cell lines were established in this study. Minced
tumour tissues ofPatients 1, 2 and 3, and cells obtained from
the pleural effusion of Patient 4 were placed into culture
dishes in RPMI 1640 medium supplemented with 10% foetal
calf serum (RPMI/FCS). When cell growth became stable
after several passages, cloning was carried out twice. Cells
were treated with 0.25% trypsin, and 100 cells were suspend-
ed in 1Oml in medium and plated 1Ocm dishes. Single cells
were picked with a capillary pipette under reverse micro-
scopy, and each was transferred to a well of a 96-well plate,
and tumour cell lines were established. Chromosomes were
analysed by trypsin G-banding as previously described
(Homma et al., 1989). In addition to these new ES lines, four
previously established ES lines were used. There were SCCH-
196 (Homma et al., 1989), W-ES (Fujii et al., 1989), RD-ES,
and SK-ESI. Both SCCH-196 and W-ES have been shown to
have a chromosomal translocation with t(I1;22)(q24;ql2).
RD-ES and SK-ES1 (Bloom, 1972) were obtained through
the American Type Culture Collection (Rockville, Md,
USA).
Transplantation into nude mice
Ten million tumour cells were transplanted into the backs of
Balb/c nude mice according to the method previously
described (Hata et al., 1980). When tumours reached to
10 mm in diameter, they were removed and processed for
further characterisation.
In vitro diferentiation experiment
Cells were plated on Lab-Tech 2-chamber slides or into
75 cm2 culture flasks in RPMI/FCS at 1 x 104ml-' with or
without 2.5 mM N6-02-dibutyryladenosine-3;5'-cyclic mono-
phosphate (db-cAMP). db-cAMP was prepared by diluting a
stock 125 mM solution dissolved in RPMI 1640. After 1 week
of cultivation, the morphology of the cells on the chamber
slides was observed, and cells were processed for immuno-
histochemistry and electron microscopy. Cells in the flasks
were collected and were tested for indirect immunofluore-
scence with 5C1 1 followed by flow cytometrical analysis
(Epics-Profile, Coulter Corp., Haileah, Fl, USA) as described
previously (Hara et al., 1989).
Results
Original tumours
Patients 1, 2 and 3 were treated by combined chemotherapy
and/or radiotherapy before the tumours were removed. By
light microscopy, they were found to be composed of small,
round cells with clear cytoplasm and round to oval nuclei
(Figure la). Most tumour cells of all three patients con-
tinued fine cytoplasmic granules which were positive in the
periodic acid-Schiff reaction. They were digested with dia-
state, suggesting glycogen granules. In the tumours ofpatient
3, rosette-like structures were occasionally observed. Immuno-
histochemically, they all reacted with 5Cl1 (Figure Ib) but
not with anti-68 kD NFP, anti-200 kD NFP, or anti-desmin.
By electron microscopy, no evidence for neuronal differenti-
ation such as neurosecretory granules or microtubules was
observed. From these results the tumours in Cases 1, 2 and 3
Figure 1 Histology of ES (Case 1, Original tumour of NCR-
EWI), a, Hematoxylin eosin staining, showing small, round cells
with round to oval nuclei and clear chromatin (original magnifi-
cation x 100), b, 5C1I staining (original magnification x 100).
were diagnosed as ESs. In Case 4, only pleural effusion was
obtained for analysis, but the tumour cells reacted with 5C1 1
and not with anti-200 kD NFP. Immunohistochemical find-
ings as well as clinical manifestations favoured the diagnosis
of ES in Case 4.
The tumours in Cases 3 and 4 were malignant small cell
tumours of the thoracopulmonary region, but they had no
evident phenotypical features of neurogenic tumours.
Establishment ofcell lines
Four in vitro ES cell lines were newly established from
tumours of seven patients with ES. All four lines, NCR-
EWI, -EW2, -EW3, and -EW4 have been stably growing for
more than 121, 78, 73 and 47 passages, respectively. NCR-
EWI grew with weak attachment to the bottom of the plastic
flask and had round to spindle shaped cells. NCR-EW2 and
-EW4 grew attached to the flask as well, with polygonal
shaped cells, but occasionally they had cytoplasmic processes.
In NCR-EW4, large flattened cells were occasionally seen.
On the other hand, NCR-EW3 did not attach to the flask
and grew as floating aggregates of cells in the medium.
Cloning was carried out by the usual method and a few
clones were obtained from each cell line. These cloned cells
were shown to have cytological and immunocytological
features similar to those of the mother cells morphologically
and immunophenotypically. NCR-EW2, -EW3 and -EW4
reacted with 5CII, whereas NCR-EWI did not. NCR-EWI
was derived from the transplanted tumour in Case 1 in nude
mice which was used for the screening when 5Cll was pro-
duced. Through some unknown mechanism, 5Cl1 expression
was lost during in vitro cultivation. NCR-EWI, -EW2, and
-EW3 did not react with anti-68 kD or anti-200 kD NFPNEURONAL DIFFERENTIATION OF EWING'S SARCOMA 1027
MoAb. However, in NCR-EW4, some, but not all cells were
found to be reactive with anti-200 kD NFP MoAb. When the
staining profile was carefully examined, it was found that
200 kD NFP positive cells were located at the margin of the
cell aggregates. As was stated above, the original tumour of
NCR-EW4 (Case 4) was not positive for NFPs. Therefore,
NCR-EW4 acquired the capability of differentiation towards
the neuronal direction which becomes evident under certain
culture conditions.
Doubling time was measured and chromosomal analysis
was performed for NCR-EWI, -EW2, -EW3 and -EW4 at
104, 61, 56 and 30 passages, respectively and are summarised
in Table I. In particular, a typical t(ll;22)(q24;ql2)
chromosomal translocation was identified in NCR-EW2
(Figure 2). This abnormality was not observed in the other
ES lines but an abnormality linked to chromosome No. 22
(+ der(22)) was identified NCR-EW1 and -EW3. Of 15 meta-
phase cells from NCR-EW4, all had abnormal karyotypes
but no specific abnormality could be detected. These results
are shown in Table I.
The four new ES lines were examined for tumourigenicity
in nude mice. Ten million tumour cells of each line were
subcutaneously injected into five nude mice and all four lines
produced tumours, in all the recipient mice. Histological
examination revealed that the transplanted tumours were
morphologically consistent with typical ES and no neuronal
differentiation was observed by immunohistochemical and
ultrastructural examination.
In vitro differentiation
In addition to the four cell lines established in our labor-
atory, four other ES lines were used to examine their ability
to differentiate in a neuronal direction. All these four cell
lines, SCCH-196, W-ES, RD-ES and SK-ES1, reacted with
5CIl. All lines except W-ES were negative for NFPs. W-ES
was positive for both 68 kD and 200 kD NFPs although its
original tumour was negative for these proteins (Fuji et al.,
1989).
When treated with db-cAMP, a morphological change was
observed in NCR-EW2, RD-ES and SK-ES1. As is shown in
Figure 3a, many cells of NCR-EW2 had elongated cytoplas-
mic processes after 3 days of treatment. A similar change was
observed in RD-ES and SK-ESI. No apparent morphological
Table I Immunohistochemical reactivities and cytogenetical analyses of established cell line
NFP
Cell lines SCII 68kD 200kD Des D.T. Chromosome A/B
NCR-EW1 48 47,XY,-19,-22,+der(l9)t(1;19)(ql2;ql 1), 4/6
+der(l9)t(19;?)(pl 1;?), +der(22)t(?;22)(?;ql 1.2)
NCR-EW2 + - - - 34.3 50,XY,+8,-13,+ 15,-17,+ 18,+ 18,+20,-21, 2/17
del(3)(p21),t(l1;22)(q24;ql2), +2mark
NCR-EW3 + - - - 55.4 41,del(X)(q26),-Y,-2,-4,-6,-9,-9,-10,-13,-14, 5/12
-16,-17,-19,-22, del(3)(p12),del(8)(q22),del( 1)(p12.2),
+der(16)t(l;16)(ql l;ql 1),+der(6)t(6;?)(p12;?), +der(9)t
(9;?)(q34;?), +der(22)t(?;22)(?;q12), +4mark
NCR-EW4 + - + - 40 others ?/15
NFP; neurofilamentprotein, Des; desmin, D.T.; doubling time (hour), A: Cellshavingchromosomal abnormalities,
B: Examined cells at metaphase.
Figure 2 Chromosomal analysis ofNCR-EW2. Several pattern ofchromosomal abnormalities were observed (arrows). NCR-EW2
has translocation t(I1;22)(q24;q12) (arrow heads).1028 S. HARA et al.
change was observed when cells were cultured in the absence
of db-cAMP. Immunohistochemically, 200 kD NFP was
detected in db-cAMP treated NCR-EW2, RD-ES and SK-
ESI as shown in Figure 3a. In particular, 200 kD NFP was
usually detected in the elongated processes of tumour cells
(Figure 3a), and 5C1 1 also reacted with them (Figure 3b).
However, 68 kD NFP was not detected in db-cAMP treated
cells. No NFP was detected immunohistochemically in the
control culture. Electron microscopic observation ofdb-cAMP
treated SK-ES1 (Figure 4a) revealed that microtubules in the
cytoplasmic processes had clearly increased as compared with
the control cell (Figure 4b) but neurosecretory granules were
not found. When NCR-EW4 and W-ES were treated in the
same manner, the number of 200 kD NFP positive cells
increased. NCR-EW1, NCR-EW3 and SCCH-196, on the
other hand, showed no morphological and immunohisto-
chemical changes caused by the same treatment.
Expression of 5C11 by ES lines during in vitro treatment
with db-cAMP was studied by flow cytometrical analysis. As
is shown in Figure 5, the fluorescence intensity of 5C11 was
weaker in the four cell ines (NCR-EW3, NCR-EWr, SCCH-
196 and SK-ESI) than in the control culture. No definitive
change in 5C11 expression was observed in NCR-EW2, RD-
ES, and W-ES. These results are shown in Table II.
Discussion
Differentiation diagnosis of ES and PNETs is often quite
difficult because of their similar histological features (Triche
& Cavazzana, 1987). Recently, they have been considered to
be closely related because the same chromosomal abnorma-
lities and the same proto-oncogene expression have been
Figure 3 In vitro neuronal differentiation of ES lines. 200 kD
NFP was usually detected in the elongated processes of NCR-
EW2, a, and 5C11 also reacted with them, b, after db-cAMP
treatment (original magnification x 100).
found in ES and PNET (Aurius et al., 1983; Turc-Carel et
al., 1983; Whang-Peng et al., 1984; McKeon et al., 1988). We
recently described the development of a new monoclonal
antibody 5Cll which detects an 81,000 dalton protein cell
surface expressed on ES cells (Hara et al., 1989). We have
shown that ES can be clearly distinguished from PNET by
5Cll reactivity. Diagnostic criteria for PNET, as reported
previously, include the ultrastructural and immunohisto-
chemical findings of neurogenic tumours at initial diagnosis
such as the ultrastuctural identification of neurosecretory
granules and positive staining with anti-NFP antibodies. The
evident relationship to neurogenic tissue further supports the
diagnosis of PNET (Jaffe et al., 1984; Schmidt et al., 1985;
Shinoda et al., 1988). ES, therefore, can be diagnosed as a
tumour with no evidence of neuronal differentiation as stated
above. By this criterion, 5C11 reacts with ES, but not with
PNET. Such a strict diagnostic criterion is of particular
importance when the biological characteristics of these
tumours are studied.
The purpose of the present study was to determine the
differentiation capability of ESs. For this purpose, eight ES
cell lines including four newly established ones, NCR-EW1,
-EW2, -EW3 and -EW4 established from extraosseous ESs
were used. The pathologic characteristics of their original
tumours satisfied the criteria referred to above (Navas-Pala-
cios et al., 1984). Thus, the original tumours of all the new
ES cell lines were 5C11 positive, but had no evident charac-
teristics of neurogenic tumours. In all of the new lines except
a
Figure 4 Electron microscopic observation of SK-ESI cells. a,
db-cAMP treated SK-ESI, b, control cell (original magnification,
a; x 1300, b; x 1,000).NEURONAL DIFFERENTIATION OF EWING'S SARCOMA 1029
NCR-EWl 5C1 1 expression has been stable for a long period
of time. Reliability of 5Cl staining was also demonstrated
in other ES cell lines already established. In contrast, cell
lines established from PNET, NCR-PNI (established in our
laboratory from a sciatic nerve tumour in a 2 month old girl;
manuscript in preparation) and PNET-Muraoka (provided
by A. Nakagawara, Department of Pediatric Surgery, Kyu-
shu University School of Medicine, Fukuoka, Japan; Hachi-
tanda et al., 1990) were negative for 5Cll (data not shown).
Some NCR-EW4 cells were found to express 200 kD NFP,
although their original tumours were negative for the protein.
Similarly, in W-ES, expression of 200 kD NFP was observed




Figure 5 Expression of 5Cl of ES cells was analysed by flow
cytometer. a, b; SK-ESI, c, d; NCR-EW2. Cells were reacted with
5Cll (ii) not with class matched control antibody RI-IOB5 (i)
(Matsuura et al., 1984). The x-axis shows the log green
fluorescence intensity and y-axis represents the relative cell
number. Not clearly decreased fluorescence intensity in SK-ES1
cells treated with db-cAMP, b, comparing with control culture, a,
and unchanged intensity with, d, or without, c, db-cAMP treat-
ment in NCR-EW2 cells.
Table II Characteristics ofdifferentiation ofEwing's sarcoma
Immunostaining
Group Cellline 5C1J 68kD-NFP 200-NFP Chromosome
1 W-ES + + + t(ll;22)
NCR-EW4 + (+) - + others
2 NCR-EW2 -(-) -(+) t(l1;22)
RD-ES + -(-) -(+)
SK-ESI + -(-) -(+)
3 NCR-EW3 + (+) -(-) -(-) +der(22)
SCCH-196 + (+) -(-) -(-) t(l1;22)
NCR-EW1 + (+) -(-) -(-) +der(22)
Group 1: potential neuronaldifferentiation inanestablishedcellline;
2: potential neuronal differentiation in an in vitro differentiation
experiment; 3: no evidence ofneuronal differentiation. +; positive, -;
negative, 4,; reducing, (); after db-cAMP treatment.
al., 1989). These results show that some ESs which do not
have any characteristics of neurogenic tumours at their initial
diagnosis can express neuronal markers in cell culture.
Chromosomal analysis was performed on all new cell lines
but the typical translocation involving t(ll;22)(q24;ql2) was
seen only in NCR-EW2. However, a chromosomal abnor-
mality, + der(22), was identified in NCR-EWI and -EW3.
Therefore it is likely that a structural change in chromosome
22 other than t(l 1;22)(q24;ql2) is another characteristic
feature of ESs. Precise characterisation of chromosomal
abnormality will be fully described elsewhere (Kaneko et al.,
manuscript in preparation).
Biological characteristics of ES were further determined by
in vitro differentiation of eight ES cell lines stimulated with
db-cAMP. Interestingly, a heterologous response to db-
cAMP was observed. Three cell lines, NCR-EW2, RD-ES
and SK-ESI were shown to have morphological changes
which were accompanied by the new expression of 200 kD
NFP when stimulated with db-cAMP. In NCR-EW4 and
W-ES, 200 kD NFP positive cells were clearly increase by
db-cAMP treatment. On the other hand, NCR-EWI, -EW3
and SCCH-196 showed no definitive change after the same
treatment in repeated experiments. It is of interest to com-
pare our results with those of Cavazzana et al. (1987). By
using five ES lines, they clearly demonstrated the capability
of ES to differentiate in the neural direction after db-cAMP
treatment. All the cell lines they used were derived from
osseous ESs with a chromosomal abnormality involving
t(11;12). Similarly, in our study, some ES lines could be
induced to differentiate into 200 kD NFP positive neuronal
cells. However, it must be emphasised that three cell lines
could not be induced to differentiate by the same treatment.
In addition, there was no correlation between differentiation
capability and chromosomal abnormality. Therefore, it is
likely that ES is a heterogeneous group with neuronal differ-
entiation capability in at least three categories: (1) ES with
potential neuronal differentiation which becomes evident in
an established cell line, (2) ES with potential neuronal differ-
entiation which becomes evident in an in vitro differentiation
experiment and (3) ES with no evidence of neuronal differ-
entiation even in a cell line (Table II). We propose this
hypothesis in studying the biology of ES and its closely
related tumour, PNET.
The relation between ES and PNET is still a problem to be
solved. Recently, Marina et al. (1989) described putative
diagnostic criteria for PNET. However, other authors show
that some ESs can satisfy their criteria. For examples, some
ESs show chromosomal abnormality t(l 1;22)(q24;q12) as
shown here and in other reports and two PNET cell lines,
NCR-PNl and PNET-Muraoka, do not have such a trans-
location (unpublished observation; manuscript in prepara-
tion). Although they included neuron-specific enolase (NSE)
and Leu 7 reactivity, we excluded these markers from our
study. None of the antibodies available at present can speci-
fically recognise the yy-subunit of NSE, the form really
specific to neuronal tissues, and we cannot rule out the
possibility of a reaction with the ay-subunit (Dranoff &1030 S. HARA et al.
Bigner, 1984; Vinores et al., 1984; Schmechel, 1985; Shimada
et al., 1988). When we stained malignant small round cell in
childhood tumour (neuroblastomas, rhabdomyosarcomas, ESs
and malignant lymphomas) with anti-NSE antiserum (Dako-
patts), in fact, specific reactivity could not be obtained (data
not shown). In addition, Leu 7 is not a specific marker for
neuronal cells (Abo & Balch, 1981; Abo et al., 1982). We
therefore propose to use NFPs and 5Cll as immunohisto-
chemical probes for differentiating between ES and PNET at
the initial diagnosis.
It is ofparticular importance to determine as many charac-
teristics (histology, immunohistochemistry, oncogene, chro-
mosome, and establishment of cell lines) of these unique
tumours as possible. Only through such extensive study the
real features of ES and PNET can be obtained, and these
features in turn should be utilised to established more effec-
tive therapeutic regimens. It is also important that investiga-
tors obtain a variety ofprobes to examine ES and PNET and
in this regard we are ready to distribute monoclonal antibody
5C11 for more sophisticated study of this particular type of
tumour.
We wish to thank Professor Osahiko Abe and Assistant Professor
Jotaro Yokoyama, Department of Surgery, Keio University School
of Medicine, for their scientific discussion, and Takashi Sekine,
Division of Electron Microscopy, Tokai University School of Medi-
cine, for his technical assistance. This work was supported by
Grants-in-Aid for Cancer Research (3-6) from the Ministry of
Health and Welfare and from the Ministry of Education of Japan,
together with funds provided by the Entrustment of Research Pro-
gram of the Foundation for Promotion of Cancer Research of
Japan.
References
ABO, T. & BALCH, C.M. (1981). A differentiation antigen of human
NK and K cells identified by a monoclonal antibody (HNK-1). J.
Immunol., 127, 1024.
ABO, T., COOPER, M.D. & BALCH, C.M. (1982). Postnatal expansion
of natural killer and killer cell population in humans identified by
the monoclonal HNK-1 antibody. J. Exp. Med., 155, 321.
ANGERVALL, L. & ENZINGER, F. (1975). Extraskeletal neoplasma
resembling Ewing's sarcoma, Cancer, 36, 240.
AURIUS, A., RIMBANT, C., BUFFE, D., DUBOSET, J. & MAZA-
BRAUD, A. (1983). Chromosomal translocation in Ewing's sar-
coma. N. Engi. J. Med., 309, 496.
BLOOM, E.T. (1972). Further definition by cytotoxicity tests of cell
surface antigens of human sarcomas in culture. Cancer Res., 32,
906.
CAVAZZANA, A.O., MISER, J.C. & JEFFERSON, J. (1987). Experi-
mental evidence for a neural origin of Ewing's sarcoma of bone.
Am. J. Pathol., 127, 507.
DEHNER, L.P. (1986). Peripheral and central primitive neuroectoder-
mal tumors. A nosological concept seeking a consensus. Arch.
Pathol. Lab. Med., 110, 997.
DRANOFF, G. & BIGNER, D.D. (1984). A word of caution in the use
of neuron-specific enolase expression in tumor diagnosis. Arch.
Pathol. Lab. Med., 108, 535.
EWING, J. (1921). Diffuse endothelioma of bone. Proc. N.Y Pathol.
Soc., 21, 17.
FUJII, Y., HONGO, T., NAKAGAWA, Y. & 5 others (1989). Cell cul-
ture of small round cell tumor originating in thoracopulmonary
region: evidence for derivation from a primitive pluripotent cell.
Cancer, 64, 43.
HACHITANDA, Y., TSUNEYOSHI, M., ENJOJI, M., NAKAGAWARA,
A. & IKEDA, K. (1990). Congenital primitive neuroectodermal
tumor with epithelial and glial differentiation. Arch. Pathol. Lab.
Med., 114, 101.
HARA, S., ISHII, E., TANAKA, S. & 4 others (1989). Monoclonal
antibody specifically reactive with Ewing's sarcoma. Br. J.
Cancer, 60, 875.
HATA, J., UEYAMA, Y., TAMAOKI, N. & 5 others (1980). Human
yolk sac tumor serially tranplanted in nude mice: its morphologic
and functional properties. Cancer, 46, 2446.
HOMMA, C., KANEKO, Y., SEKI, K., HARA, S., HATA, J. & SAKURAI,
M. (1989). Establishment and characterization of a small round
cell sarcoma cell line, SCCH-196, with t(11;22)(q24;ql2). Jpn. J.
Cancer Res., 80, 861.
JAFFE, R., AGOSTINI, B.S. Jr, SANTAMARIA, M. & 4 others (1984).
the neuroectodermal tumor of bone. Am. J. Surg. Pathol., 8, 885.
JUERGENS, H., BIER, V., HARMS, D. & 8 others (1988). Malignant
peripheral neuroectodermal tumors. A retrospective analysis of
42 patients. Cancer, 61, 349.
MARINA, N.M., ETCUBANAS, E., PARHAMS, D.M., BOWMAN, L.C. &
GREEN, A. (1989). Peripheral primitive neuroectodermal tumor
(Peripheral neuroepithelioma) in children. A review of St Jude
experience and controversies in diagnosis and management.
Cancer, 64, 1952.
MATSUURA, A., ISHII, Y., YUASA, H. & 4 others (1984). Rat T
lymphocyte antigens comparable with mouse Lyt-l and lyt-2, 3
antigenic systems: characterization by monoclonal antibodies. J.
Immunol., 132, 316.
McKEON, C., THIELE, C.T., ROSS, R.A. & 4 others (1988). Indistin-
guishable patterns of protooncogene expression in two distinct
but closely related tumors: Ewing's sarcoma and neuroepithe-
lioma. Cancer Res., 48, 4307.
NAVAS-PARACIOS, J.J., APARICIO-DUQUE, R. & VALDtS, MD.
(1984). On histogenesis of Ewing's sarcoma. An ultrastructural,
immunohistochemical, and cytochemical study. Cancer, 53, 1882.
SHIMADA, M., NEWTON, W.A, SOULE, E.H., QUALMAN, S.J.,
AOYAMA, C. & MAURER, H.M. (1988). Pathologic features of
extraosseous Ewing's sarcoma: a report from the Intergroup
Rhabdomyosarcoma Study. Human Pathol., 19, 442.
SCHMECHEL, D.E. (1985). y-subunit of the glycolytic enzyme eno-
lase: non-specific or neuron-specific? Lab. Invest., 52, 239.
SCHMIDT, D., HARMS, D. & BURDASH, S. (1985). Malignant peri-
pheral neuroectodermal tumours of childhood and adolescence.
Virchows Arch. (Pathol. Anat.), 406, 350.
SHINODA, M., TSUTSUMI, Y., HATA, J. & YOKOYAMA, S. (1988).
Peripheral neuroepithelioma in childhood. Arch. Pathol. Lab.
Med., 112, 1155.
TAFFT, M., VAUTER, G.F. & MITUS, A. (1969). Paravertebral small
round cell tumors in children. Radiology, 92, 1501.
TRICHE, T.J. & CAVAZZANA, A.O. (1987). Pathology of pediatric
oncology. In Lipinscott, ?. (ed.), Principles and Practice ofPediat-
ric Oncology, 93.
TURC-CAREL, C., PHILIP, I., BERGER, M.P. & LENOIR, G.M. (1983).
Chromosomal translocation in Ewing's sarcoma. N. Engl. J.
Med., 309, 497.
VINORES, S.A., BONNIN, J.M., RUBINSTEIN, L.J. & MARANGOS, P.J.
(1984). Immunohistochemical demonstration of neuron-specific
enolase of the CNS and other tissues. Arch. Pathol. Lab. Med.,
108, 536.
VOSS, B.L., PYSHER, T.J. & HUMPHREY, G.B. (1984). Peripheral
neuroepitherioma in childhood. Cancer, 54, 3059.
WHANG-PENG, J., TRICHE, T.J., KNUSTSEN, T., DOUGLAS, E.C. &
ISRAEL, M.A. (1984). Chromosome translocation in peripheral
neuroepithelioma. N. EngI. J. Med., 311, 584.